Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$31.76M$31.76M+15.0% vs Q2 2022 Net Income-$42.06M-$42.06MN/M vs Q2 2022 EPS Diluted-$0.35-$0.35N/M vs Q2 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$27,165,000N/M Free Cash Flowderived-$27,443,000N/M Margins · derivedGross margin36.5%
Operating margin-133.5%+45.6 pt vs Q2 2022
Net margin-132.4%+71.6 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end